Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. is positioned for a positive financial outlook, driven by anticipated growth in the spine market and increasing sales from its Enabling Technologies segment, which may enhance overall profit margins. The company is seeing strong free cash flow generation, bolstered by its balance sheet, and has demonstrated impressive core spine growth in the U.S., outpacing the market at an estimated 10% increase in sales. Furthermore, the ongoing integration of NuVasive and in-sourcing manufacturing efforts are expected to contribute to gross margin expansion, with projections for EBITDA margins stabilizing at 34-35% by 2026.

Bears say

Globus Medical faces several significant risks that contribute to a negative outlook on its stock, including potential slower growth in the spine market and revenue dis-synergies arising from recent mergers with NuVasive and Nevro. The bear case scenario anticipates revenue growth slowing to low single digits, coupled with flat margins, while downside risks encompass competitive pressures, underwhelming product launches, and prolonged timelines for expansion into new musculoskeletal markets. Additionally, the company may experience a material decline in operating margins and challenges in capital investment for robotic systems, which could further jeopardize financial performance.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Apr 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.